FGF19 Is Coamplified With CCND1 to Promote Proliferation in Lung Squamous Cell Carcinoma and Their Combined Inhibition Shows Improved Efficacy
Lung squamous cell carcinoma (LUSC) remains as a major cause of cancer-associated mortality with few therapeutic options. Continued research on new driver genes is particularly important. FGF19, a fibroblast growth factor, is frequently observed as amplified in human LUSC, which is also associated w...
Main Authors: | Yanshuang Zhang, Tingyu Wu, Fan Li, Yirui Cheng, Qing Han, Xin Lu, Shun Lu, Weiliang Xia |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.846744/full |
Similar Items
-
LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC
by: Dongcheng Liu, et al.
Published: (2022-06-01) -
FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer
by: Ying Yang, et al.
Published: (2020-01-01) -
MiR‐646 suppresses proliferation and metastasis of non‐small cell lung cancer by repressing FGF2 and CCND2
by: Jing Wang, et al.
Published: (2020-06-01) -
Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas
by: Gerd Jomrich, et al.
Published: (2019-09-01) -
In leukemia, knock-down of the death inducer-obliterator gene would inhibit the proliferation of endothelial cells by inhibiting the expression of CDK6 and CCND1
by: Honghua Cao, et al.
Published: (2022-02-01)